These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypertension as part of the metabolic syndrome. Cheung B J Hum Hypertens; 2008 Dec; 22(12):871-4. PubMed ID: 18548089 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary and cardiovascular derangements in the obese patient. Vaughan RW Contemp Anesth Pract; 1982; 5():19-39. PubMed ID: 7053316 [No Abstract] [Full Text] [Related]
4. Cardiovascular adaptations to obesity and arterial hypertension: detrimental or beneficial? Messerli FH Int J Cardiol; 1983 Apr; 3(1):94-7. PubMed ID: 6852998 [No Abstract] [Full Text] [Related]
5. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Grassi G Hypertens Res; 2006 Nov; 29(11):839-47. PubMed ID: 17345783 [TBL] [Abstract][Full Text] [Related]
7. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
8. Part I: cardiopulmonary consequences of morbid obesity. Vaughan RW; Conahan TJ Life Sci; 1980 Jun; 26(25):2119-27. PubMed ID: 6995766 [No Abstract] [Full Text] [Related]
9. Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis. Kshatriya S; Reams GP; Spear RM; Freeman RH; Dietz JR; Villarreal D Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):72-8. PubMed ID: 19851106 [TBL] [Abstract][Full Text] [Related]
10. Hypertension in obese patients: a dysmetabolic hypertension with a possible adipocyte dysfunction mechanism. Blaj S; Stanciu S; Jurcut C; Ciobîcă L Rom J Intern Med; 2003; 41(2):103-11. PubMed ID: 15526495 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor activation in obesity hypertension. Nagase M; Fujita T Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Grassi G; Quarti-Trevano F; Seravalle G; Dell'Oro R Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):473-81. PubMed ID: 17451923 [TBL] [Abstract][Full Text] [Related]
13. Sleep apnea and obesity. Yu JC; Berger P S D Med; 2011; Spec No():28-34. PubMed ID: 21717814 [TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome and kidney disease. Ritz E Blood Purif; 2008; 26(1):59-62. PubMed ID: 18182798 [TBL] [Abstract][Full Text] [Related]
15. [Dysmetabolic symptomatic arterial hypertension and dysmetabolic disease]. Bokarev IN; Shubina OI Klin Med (Mosk); 2009; 87(8):67-71. PubMed ID: 19827536 [No Abstract] [Full Text] [Related]
16. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Rüster C; Wolf G Semin Nephrol; 2013 Jan; 33(1):44-53. PubMed ID: 23374893 [TBL] [Abstract][Full Text] [Related]
17. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Reisin E; Jack AV Med Clin North Am; 2009 May; 93(3):733-51. PubMed ID: 19427502 [TBL] [Abstract][Full Text] [Related]
18. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Vogt B; Bochud M; Burnier M Semin Nephrol; 2007 Sep; 27(5):529-37. PubMed ID: 17868790 [TBL] [Abstract][Full Text] [Related]